Trial Profile
An Extended Observational Study (P12-707: HOPE III Study) of Follow-up Survey (P12-069: HOPE II Study) of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms HOPE-3; HOPE-III; HOPEFUL-3
- Sponsors Abbott Laboratories; AbbVie; Eisai Co Ltd
- 22 Dec 2014 Status changed from active, no longer recruiting to completed reported by ClinicalTrials.gov
- 11 Apr 2014 Planned End Date changed from 1 Dec 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
- 17 Apr 2013 New trial record